Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

Experimental hematology - 1 Nov 2007

Schwemmers Sven, Will Britta, Waller Cornelius F, Abdulkarim Khadija, Johansson Peter, Andreasson Björn, Pahl Heike L

Abstract excerpt

OBJECTIVE: Presence of the JAK2V617F mutation in only 40% to 60% of patients with essential thrombocythemia (ET) underscores the heterogeneity of this myeloproliferative disorder (MPD). Several distinct mutations, either in JAK2 (exon 12) or in c-Mpl (W515L) have been described in subsets of other MPDs, polycythemia vera, and idiopathic myelofibrosis. Analogous to JAK2,V617F these mutations cause constitutive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Activation
Share to Gene Expression Profiling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation

Share to Janus Kinase 2

Share to STAT Transcription Factors

Share to STAT3 Transcription Factor

Share to Suppressor of Cytokine Signaling Proteins

Share to Thrombocythemia, Essential

Source

Open in PubMed Open full text

Identifiers

PMID: 17764814
DOI: 10.1016/j.exphem.2007.07.004
PMCID: PMC2270411

Genes

JAK2
STAT3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.PMID 17764814Read ↗

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative DisordersSemantic proximity Read ↗

Molecular analysis of phenotypic heterogeneity in JAK2V617F-positive myeloproliferative neoplasms reveals a potential target for therapy.Semantic proximity Read ↗

The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patientsSemantic proximity Read ↗

Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia.Semantic proximity Read ↗

A role for JAK2 mutations in myeloproliferative diseases.Semantic proximity Read ↗

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.Semantic proximity Read ↗

JAK-2 mutations and their relevance to myeloproliferative diseaseSemantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.Semantic proximity Read ↗

Aberrant signal transduction pathways in myeloproliferative neoplasms.Semantic proximity Read ↗

Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.Semantic proximity Read ↗

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.